Demographic, Clinical, Financial Factors Tied to GLP-1 Agonist Discontinuation
Researchers from the Evernorth Research Institute in St. Louis conducted a study to understand the prevalence of discontinuation of glucagon-like peptide 1 (GLP-1)…
South Park Skewers GLP-1 Frenzy in “End of Obesity special”
The long-running adult comedy show, South Park, recently released a special called “The End of Obesity” on Paramount+. In this…
Exploring the Efficacy of GLP-1 Receptor Agonists in Weight Management
Obesity is a growing concern worldwide, and finding effective weight management strategies is crucial for improving public health. Recent studies…
Ozempic and GLP-1s are Reshaping the Travel Industry
These groundbreaking weight loss medications have far-reaching implications, impacting not only individual health but also travel experiences and businesses. 🌎✈️…
How Does Wegovy® Work?
Let’s delve deeper into the mechanism of action for Wegovy® (semaglutide), a medication used for chronic weight management. 🌟
GLP-1 Medications: Celebrities Share Their Experiences
In recent years, GLP-1 medications have become a beacon of hope for many struggling with weight management. These drugs, including…
Ongoing Research Explores Expanding Potential of GLP-1 Drugs
While GLP-1 medications like Ozempic, Wegovy and Mounjaro have skyrocketed in popularity for treating diabetes and obesity, researchers are working…
Obesity Market Poised to Soar to $150 Billion as Supply Meets Voracious Demand
The pharmaceutical industry’s obesity market is on the verge of an unprecedented boom, with analysts projecting it could swell to…
The Dangerous Spread of #OzempicTok Influencer Culture
Social media is awash with influencers and everyday people jumping on the latest trend – using prescription weight loss drugs…
Associations of Semaglutide with Incidence and Recurrence of Alcohol Use Disorder in Real-World Populations
Introduction Semaglutide, a medication commonly used for diabetes and obesity management (marketed as Ozempic and Wegovy), has recently piqued interest…
